Low-Dose Computed Tomography (CT) Lung Screening Programs Market Report 2026

Low-Dose Computed Tomography (CT) Lung Screening Programs Market Overview

• Low-Dose Computed Tomography (CT) Lung Screening Programs market size has reached to $1.66 billion in 2025 • Expected to grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 10.9% • Growth Driver: Surge In Lung Cancer Fueling The Growth Of The Market Due To Increasing Incidence And Early Detection Needs • Market Trend: Emory Healthcare Introduces Ai-enhanced Lung Screening And Nodule Program • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Low-Dose Computed Tomography (CT) Lung Screening Programs Market?

Low-dose computed tomography (CT) lung screening programs are preventive healthcare initiatives that use low-dose CT imaging to detect lung abnormalities at an early stage. These programs enable the identification of small nodules or potential malignancies before symptoms appear, improving the chances of successful treatment. The main types of low-dose computed tomography (CT) lung screening programs include hospital-based, independent imaging centers, and mobile screening units. Hospital-based programs are organized screening initiatives conducted within hospitals to detect lung abnormalities early and improve patient outcomes. They offer services such as screening services, diagnostic follow-up services, radiology interpretation services, patient identification and risk assessment services, program management services, and telehealth and remote consultation services and utilize technologies such as standard low-dose CT screening, AI-assisted/computer-aided detection (CAD) screening, and integrated smoking cessation and screening programs. The various applications involved are early detection, risk assessment, and follow-up monitoring, and are used by several end users such as hospitals and multi-specialty clinics, standalone diagnostic imaging centers, mobile screening service providers, government and public health agencies, private healthcare networks and insurance providers, employer and corporate wellness programs, academic and research institutions, and community health centers.

What Is The Low-Dose Computed Tomography (CT) Lung Screening Programs Market Growth Forecast?

The low-dose computed tomography (CT) lung screening programs market size is expected to see rapid growth in the next few years. It will grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to growing adoption of AI-assisted CT screening, expansion of precision oncology initiatives, rising investment in mobile healthcare delivery models, increasing integration of telehealth consultation services, expanding public-private partnerships in preventive healthcare. Major trends in the forecast period include expansion of government-sponsored lung cancer screening programs, increasing adoption of mobile screening units in rural areas, rising integration of smoking cessation support with screening services, growing emphasis on risk-based patient identification, expansion of radiology interpretation and follow-up monitoring services.

Global Low-Dose Computed Tomography (CT) Lung Screening Programs Market Segmentation

1) By Type: Hospital-Based, Independent Imaging Centers, Mobile Screening Units 2) By Service: Screening Services, Diagnostic Follow-Up Services, Radiology Interpretation Services, Patient Identification And Risk Assessment Services, Program Management Services, Telehealth And Remote Consultation Services 3) By Technology: Standard Low-Dose CT Screening, AI-Assisted/Computer-Aided Detection (CAD) Screening, Integrated Smoking Cessation And Screening Programs 4) By Application: Early Detection, Risk Assessment, Follow-Up Monitoring 5) By End User: Hospitals And Multi-Specialty Clinics, Standalone Diagnostic Imaging Centers, Mobile Screening Service Providers, Government And Public Health Agencies, Private Healthcare Networks And Insurance Providers, Employer And Corporate Wellness Programs, Academic And Research Institutions, Community Health Centers Subsegments: 1) By Hospital-Based: Outpatient Department, Inpatient Department, Radiology Department 2) By Independent Imaging Centers: Standalone Imaging Clinics, Diagnostic Centers, Specialized Lung Screening Centers 3) By Mobile Screening Units: Bus-Based Screening Units, Van-Based Screening Units, Temporary Pop-Up Screening Units

What Is The Driver Of The Low-Dose Computed Tomography (CT) Lung Screening Programs Market?

The rising burden of lung cancer is expected to drive the growth of the low-dose computed tomography (CT) lung screening programs market going forward. Lung cancer is a malignancy that originates in lung tissue and is characterized by the uncontrolled growth of abnormal cells, often remaining asymptomatic until advanced stages. The increasing incidence of lung cancer is primarily driven by sustained tobacco use, along with additional risk factors such as exposure to air pollution and occupational carcinogens. Low-dose CT lung screening programs play a critical role in lung cancer management by enabling early detection of tumors in high-risk populations, particularly long-term smokers. For instance, in February 2026, according to the Australian Government, an Australia-based government department, an estimated 15,108 new lung cancer cases were diagnosed in 2025, accounting for 9.0% of all new cancer cases. Therefore, the rising burden of lung cancer is driving the growth of the low-dose computed tomography (CT) lung screening programs industry.

Key Players In The Global Low-Dose Computed Tomography (CT) Lung Screening Programs Market

Major companies operating in the low-dose computed tomography (CT) lung screening programs market are Hitachi Medical Systems America Inc., Medtronic plc, Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Inc., Mayo Clinic, Columbia University Herbert Irving Comprehensive Cancer Center, Duke University Health System, Emory Healthcare, Canon Medical Systems Corporation, RadNet Inc., University of Tennessee Medical Center, McLeod Health, Holy Cross Health, Lima Memorial Health System, Memorial Sloan Kettering Cancer Center, Independence Health System, Weill Cornell Medicine & NewYork-Presbyterian Mobile Unit, Optellum Ltd., 4DMedical Pty Ltd.

Global Low-Dose Computed Tomography (CT) Lung Screening Programs Market Trends and Insights

Major companies operating in the low-dose computed tomography (CT) lung screening programs market are focusing on developing advanced solutions, such as artificial intelligence (AI)–assisted nodule detection, to enhance early cancer detection, improve diagnostic accuracy, and streamline patient care. AI-assisted nodule detection refers to the use of machine-learning algorithms within lung screening programs to automatically identify, characterize, and prioritize pulmonary nodules on low-dose CT scans, enabling timely follow-up and intervention. For instance, in December 2025, Emory Healthcare, a US-based health system, launched the Emory Healthcare Lung Screening and Nodule Program, which integrates low-dose CT screening with AI-enhanced imaging technology. The program supports multidisciplinary care by incorporating advanced diagnostic and treatment capabilities, including robot-assisted bronchoscopy, minimally invasive lung cancer surgery, and coordinated care navigation, facilitating early diagnosis, personalized treatment planning, and improved patient outcomes across multiple metro Atlanta locations.

What Are Latest Mergers And Acquisitions In The Low-Dose Computed Tomography (CT) Lung Screening Programs Market?

In September 2023, AstraZeneca, a UK-based company that provides and supports initiatives that lead to low-dose CT (LDCT) lung screening partnered with Institute Kanser Negara's. Through this partnership, AstraZeneca and Institute Kanser Negara aim to leverage artificial intelligence technology to enhance the accuracy, efficiency, and early detection capabilities of low-dose CT lung screening programs. Institute Kanser Negara's is a Malaysia-based provides Low-Dose CT (LDCT) lung screening programs.

Regional Insights

North America was the largest region in the low-dose computed tomography (CT) lung screening programs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Low-Dose Computed Tomography (CT) Lung Screening Programs Market?

The low-dose computed tomography (CT) lung screening programs market consists of revenues earned by entities by providing services such as follow-up monitoring, risk assessment, and referral coordination. The market value includes the value of related goods sold by the service provider or included within the service offering. The low-dose computed tomography (CT) lung screening programs market includes sales of lung phantoms, protective shielding, and patient positioning aids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Low-Dose Computed Tomography (CT) Lung Screening Programs Market Report 2026?

The low-dose computed tomography (ct) lung screening programs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the low-dose computed tomography (ct) lung screening programs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.